Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3
Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3
M. Migden,C. Schmults,17 Authors,D. Rischin
2023 · DOI: 10.25251/skin.7.supp.176
SKIN The Journal of Cutaneous Medicine · 3 Citations